***Must READ DD***
Absolutely fantastic response on Yahoo to the Sweeper hit piece on Thursday. I am still working to confirm all sources and encourage people with relative links to post.
1. Brazil is building a IBIO plant for manufacturing bio therapeutics and vaccines. The brazil ( GE built) plant is Mainly IBIO's Yellow Fever vaccine that will be sold in 70 countries. Brazil’s Bio-Manguinhos/Fiocruz . The royalty-bearing license granted by iBio covers the nations of Latin America, the Caribbean and Africa. 2. China building 3 IBIO plants for manufacturing bio therapeutics and vaccines.?3. head of GE healthcare says for the next 10 to 20 years bio therapeutics and vaccines will be made on IBIO's platform. ?4. IBIO HPV vaccine patented in China. ?5. Huge pipeline. (Malaria, Hookworm, HPV, H1n1, H5n1, H7n9, Fibrosis on and on). ?6. GE Healthcare has KUBIO plant design that makes it affordable for most countries to have their own ability to make medicine through IBIO's platform. KUBioTM, an innovative off-the-shelf, modular factory designed to save manufacturers of biopharmaceuticals both time and money. KUBio’s pre-made modules 7. The Texas lab has been specifically requested to submit a proposal for the manufacture of zmapp. The experimental zmapp drug was used to treat Kent Brantly an American aid doctor and a Spanish nurse Teresa Romero. Dr. Brett Giroir expects the proposals to be ready by the 10th of November. Bill and Melinda Gates, GlaxoSmithKline, DARPA backers.?8. DARPA said in their 2014 budget that they have found a new process that allows them to deal with pandemics. "What used to take years and decades now takes days and weeks though plant production". 9) Wayne P. Fitzmaurice, Ph.D., iBio's vice president of intellectual property. "Vaccines produced by our iBioModulator™ platform have been shown to have preventive and therapeutic effects in preclinical studies, and they address a great global need for effective and less costly HPV vaccines." 10) Patented platform- patent allowance complements iBio's Australian version of the patent (serial no. 2007215082) that was issued in October of 2012. It also broadens the protection of iBio's greater patent family, particularly U.S. Patents 8,173,408 and 8,591,909, Canadian Patent 2,526,720, and European Patent 1,664,322, all of which cover compositions and uses of the company's iBioModulator vaccine platform. iBio's IP portfolio now includes a total of 12 U.S. and 18 international patents, with 13 U.S. and 36 international patent applications. iBio Spokesperson Says Any Lab that Wants to Make ZMapp Vaccine Using Plant-Based Technology Would Have to License it from iBio; Caliber has License from iBio??11) Fraunhofer is Europe’s largest application-oriented research organization. Our research efforts are geared entirely to people’s needs: health, security, communication, energy and the environment. As a result, the work undertaken by our researchers and developers has a significant impact on people’s lives. We are creative. We shape technology. We design products. We improve methods and techniques. We open up new vistas. In short, we forge the future. Fraunhofer-Gesellschaft had 22,093 employees. Fraunhofer is regarded as one of the most attractive employers in Germany. 12) Collaborating with Oswaldo Cruz Foundation (Fiocruz) - it is considered one of the world's main public Health research institutions. 13) Kanematsu Chemicals Corporation and iBio expect to bring the benefits of the unique enabling features of the iBioLaunch platform to the most innovative companies and important biologic products in the Japanese pharmaceutical industry 14) Epidemics and pandemics have been with this planet for eons and they haven't been getting better. In fact, the viruses and bacteria mutate much faster than ever before. That is why IBIO's technology is essential in trying to keep up with demands NO MATTER WHAT GERM causes an epidemic. 15) Their technology has found a way to produce many vaccines and therapeutic cures much faster, cheaper, in greater quantity and purer. Infrastructures growing in Japan, Europe, China ,Brazil and the us 16) They have streamlined this process so well that they can produce vaccines, etc. in a month or so, which is way faster than the former animal/bio-reactor process. 17) ZMapp knows the future and has stated they are the future. IBIO's iBioLaunch and BioModulator are trying and keep up with the extreme demands. Panted technology makes perfectly folded proteins of choice for biopharmaceuticals, is a lot quicker, cheaper and better than the other technologies. 18) the next MEGA-PHARMA, and platform to change to Plantibodies 19) Kanematsu-Japan, Oswaldo Cruz Foundation-brazil, Fraunhofer is Europe, China building 3 IBIO plants , GE KUBIO MODs can be worldwide in 14 to 18 months . 20) plants are no longer genetically modified but simply “infiltrated”—submerged in solution—with a modified plant virus that reprograms them to make the desired pharmaceutical protein. Once infiltrated, leaves begin producing drugs in just hours. Within days, they’re harvested, ground up, and filtered, and the medicine is purified. Disruptive and big pharma knows it 21) Caliber can produce an antibody-infused tobacco plant in just weeks.?Photo by Dan Winters for Fortune iBio possesses technology which genetically alters plants so they produce humanized antibodies used to make drugs like ZMapp. 22) According to Mr. Erwin, "iBio has exclusive rights to technology directly relevant to increasing yields and accelerating production of anti-Ebola antibodies and vaccines, issued U.S. patents that cover important processes needed for production of such products in plants, and a longstanding and productive relationship with Caliber Biotherapeutics. We expect to perform an important role in the emergency response to the current outbreak and to see our technology and products used in other important human healthcare applications in the future." 23) Robert Erwin - "Technology used to produce the ZMapp antibodies in plants is covered by issued U.S. patents owned by iBio, and iBio also has additional proprietary technology that can be applied to increase the antibody yields over current levels. However, we cannot speculate on contracts that might or might not be awarded."
